Analysts Set Cellectis S.A. (NASDAQ:CLLS) Price Target at $7.00

Cellectis S.A. (NASDAQ:CLLS) has been given an average recommendation of “Moderate Buy” by the six ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $7.00.

A number of research analysts have recently issued reports on the company. Barclays initiated coverage on Cellectis in a research note on Thursday, May 28th. They set an “overweight” rating and a $9.00 price objective on the stock. Citizens Jmp reissued a “market outperform” rating and issued a $8.00 target price on shares of Cellectis in a research note on Tuesday, April 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a report on Friday.

Institutional Trading of Cellectis

Hedge funds and other institutional investors have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Cellectis by 228.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock valued at $5,856,000 after acquiring an additional 3,284,409 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Cellectis in the fourth quarter valued at $15,385,000. Citadel Advisors LLC purchased a new position in Cellectis during the 3rd quarter valued at $633,000. Marshall Wace LLP increased its position in Cellectis by 1,610.3% during the 4th quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock valued at $864,000 after purchasing an additional 168,038 shares during the period. Finally, Millennium Management LLC raised its holdings in Cellectis by 61.9% in the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 22,080 shares in the last quarter. Institutional investors own 63.90% of the company’s stock.

Cellectis Stock Up 3.5%

Shares of CLLS opened at $2.69 on Friday. The firm has a market cap of $269.91 million, a P/E ratio of -4.01 and a beta of 2.88. The stock has a 50 day simple moving average of $3.19 and a two-hundred day simple moving average of $3.62. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.52 and a quick ratio of 1.52. Cellectis has a 1 year low of $1.79 and a 1 year high of $5.48.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.08. The firm had revenue of $7.55 million during the quarter, compared to analyst estimates of $11.04 million. Cellectis had a negative net margin of 89.51% and a negative return on equity of 80.66%.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.